{"name":"Camurus AB","slug":"camurus-ab","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"Lanreotide ATG","genericName":"Lanreotide ATG","slug":"lanreotide-atg","indication":"Acromegaly","status":"phase_3"}]},{"name":"Pain","slug":"pain","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"CAM2029","genericName":"CAM2029","slug":"cam2029","indication":"Opioid use disorder (maintenance treatment)","status":"phase_3"}]}],"pipeline":[{"name":"Lanreotide ATG","genericName":"Lanreotide ATG","slug":"lanreotide-atg","phase":"phase_3","mechanism":"Lanreotide is a somatostatin analog that binds to somatostatin receptors to inhibit the secretion of growth hormone and other hormones.","indications":["Acromegaly","Neuroendocrine tumors (carcinoid syndrome)","Gastroenteropancreatic neuroendocrine tumors"],"catalyst":""},{"name":"CAM2029","genericName":"CAM2029","slug":"cam2029","phase":"phase_3","mechanism":"CAM2029 is a long-acting buprenorphine formulation designed to provide sustained opioid receptor agonism for opioid use disorder treatment.","indications":["Opioid use disorder (maintenance treatment)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMihwJBVV95cUxNUFE1TWVKZ0VoNm9tVG10Rk50SzZuTnJKTmNPajZScVg1ZHVaS0ZYQ09ncEoxSGFSQ2hMOFZrZEhpZWhMd3hpZVRXSjlpODVGVmRJUGN0aXBBaEtfMnR0ZVBFLWVyV3FlZ0JTTFc3dmVCMHNJQUxxaWR1LUhsR2tLa2R3T3Q2UkFkQXJaOVlzRkxwOEptTFM2Zi1seXpBa2Q0Q2FDS29NSDh5aWJhWllKR19Ib0pTYWwzTHBYRDBqMFVYMC1jR2ZLbm5HWkU1bm5pYUkwdnlHWFpDa21tcVU1d19PTThxX0VLWUFHYXVxaU56WFI3NTFjRGxtZ3JiLXhRVl9RVVA5QQ?oc=5","date":"2026-02-24","type":"pipeline","source":"The Malaysian Reserve","summary":"Acromegaly Market Poised for Significant Expansion During the Forecast Period (2026-2036) as New Treatment Options Emerge | DelveInsight - The Malaysian Reserve","headline":"Acromegaly Market Poised for Significant Expansion During the Forecast Period (2026-2036) as New Treatment Options Emerg","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-02-18","type":"pipeline","source":"simplywall.st","summary":"These Analysts Just Made A Sizeable Downgrade To Their Camurus AB (publ) (STO:CAMX) EPS Forecasts - simplywall.st","headline":"These Analysts Just Made A Sizeable Downgrade To Their Camurus AB (publ) (STO:CAMX) EPS Forecasts","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-01-08","type":"pipeline","source":"simplywall.st","summary":"Declining Stock and Solid Fundamentals: Is The Market Wrong About Camurus AB (publ) (STO:CAMX)? - simplywall.st","headline":"Declining Stock and Solid Fundamentals: Is The Market Wrong About Camurus AB (publ) (STO:CAMX)?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxNdDBzUWRpMlpyZDI4V0h6Tll5VW8wYmtHazB0TkdCMjNLYV9vdHNxWHlLZkVrNUZweFpWQ0NLWW5JRmc5d01BQXBKbllNaWl0M0dURmR2Q19RVjBNZzRKOHVGVU0tdUxGZ2VWVGN1XzU1b1FlTXJiOXhYOTJONV9CRThMVHhpZW91eUJjSldkZkM3dEhWWE5XdmJlQVdPaGhGcF9HWlF2UTZldmItMl94SDFQZ0RiUGdsSWlVaFZ6RFQ3Z3c?oc=5","date":"2025-09-16","type":"trial","source":"Healio","summary":"‘Promising’ new data could change treatment landscape for some rare diseases - Healio","headline":"‘Promising’ new data could change treatment landscape for some rare diseases","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxPSlRrZUk3MHdNV3FsWnFTN3NvaG9hcmFEQWlHeGNkZnJqWkxxZk9GODFuQWhxU2lyVzlLTFhNSVJWS1NzYzkzMHdLcWttMVEyYmRKXzRuSFJTSjNRMUJONmZvekQ4T3RKZlBaV2I0TWNkZk5EY1FqYXN2My1sTEJVYzRkdUhPMUpTZEhPREN0MElnREk1WFU5RQ?oc=5","date":"2025-09-12","type":"deal","source":"Modern Diplomacy","summary":"Big Pharma Deal: Swedish Camurus to Acquire US Braeburn? - Modern Diplomacy","headline":"Big Pharma Deal: Swedish Camurus to Acquire US Braeburn?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0AFBVV95cUxPSHVCdEd0U2NnUzBCeVV5czFYa0RHQ09uMUtoaElfQ0NXaHdPckZZUzF4akZweUFKc2QxM2Jlam9RR0RZWUtqb2dsVGFacU9XZDM5QjNQWG5ScGtCMFA4QlhEUDNSeUdHdjViWnNvN1FHYkItUHFJYklPbUczd2FndHlYN1Z5dU9SRE82LXk3NERzYVB2cGtkeVhTQWk4YkVURDFNdHZZT0NrbUk5S1RBeUNrRDdSNE90LUQwcndDaUk2cTlKNjlQa3VpSUdDdXFK?oc=5","date":"2025-09-12","type":"deal","source":"EU Reporter","summary":"Swedish Biotech Camurus in Talks to Buy US-Based Braeburn in $1 Billion Opioid Market Bet - EU Reporter","headline":"Swedish Biotech Camurus in Talks to Buy US-Based Braeburn in $1 Billion Opioid Market Bet","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxQU1JQMGpPZjRmSldFWUJxUUNocE05LXU4VV9PdVp5U2V3cDJVa1YtRXRIYjlhbWdHY3d5a0dCd1NUUnhOUGlnRGYzcWk5d3N2eEpzNzJya21WWFRvcHBjNG1ITk5OQjFxOHl0Y3l5TXV5dGhaUDlSaWtfQ09pSGlhdWFCMmJnUHFyRG1mVU5oSVdDQQ?oc=5","date":"2025-04-21","type":"pipeline","source":"Insightace Analytic","summary":"Peptide�drug Conjugates (PDCs) Market Share, Size, Growth and Forecast to 2034 - Insightace Analytic","headline":"Peptide�drug Conjugates (PDCs) Market Share, Size, Growth and Forecast to 2034","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiygFBVV95cUxOLUpwbmMzS21adDluMUFfTWo3X3lzYmprV2pFTDFNeUlabGlKbnVxR010aUhGY1Qtdnltcno1blExWG04M1F1a0lNWFlLeUFOOTFnMnluTnROUnVjN2NjNG51QXk2Q0tzQWZ1OG91VEpDNVJfdlFjYXhiY0tLTFYwN25FLVNxLTI1Z1ZrenNJa0VJYkNjVFM3bXBsdjA1dzVzaldQRzhlZzVfVlQ0NzNIQ3RuMDZnallBYy1STHlubTlCcXlmMUpNdGJR?oc=5","date":"2024-10-22","type":"regulatory","source":"Reuters","summary":"US FDA declines to approve Camurus' rare hormone disorder drug - Reuters","headline":"US FDA declines to approve Camurus' rare hormone disorder drug","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxQaDBUbldhcUNUSFRicGtHck10OXdPaWZodkU5QmNHTmlqYzE2MWI2QTZ4anZ1YlFFaEs4M0NHSmt6NWhMYmdvRGVjN1dMWUhHc2pqVG52SjJGeWhfREE3ZG8yNXotRFItVnFnRUtJUk0tZkxIamVfV2UySlVZMGw3RzhsT3ZKUHhXTVVrbnVqanVDTVdlNV81bTR0TG1NU1FfNGxYdXBpLXpLeFBxWDB1dENINmkyRXR2dnNGRDFuNA?oc=5","date":"2024-10-22","type":"regulatory","source":"Fierce Pharma","summary":"FDA stymies Camurus' hormonal disorder drug due to 3rd-party manufacturing issues - Fierce Pharma","headline":"FDA stymies Camurus' hormonal disorder drug due to 3rd-party manufacturing issues","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMie0FVX3lxTFBITHlScGt5YU9pMjd2REQwRUpBcWVBSDFIRmZiWlNMb2xBYm9qMVpUaGExU3NjOHoxakhTemtaNkdxTnE2eHhQeVBGM0UtOXczalJCN1dmUTY4X003YWVMdEhZeVA4djhnSGZ5OFpqQWkxUGZpX0o3OEFoZw?oc=5","date":"2024-01-24","type":"pipeline","source":"marketscreener.com","summary":"Camurus AB: Shareholders Board Members Managers and Company Profile | SE0007692850 - marketscreener.com","headline":"Camurus AB: Shareholders Board Members Managers and Company Profile | SE0007692850","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxOX0owd0JITW9KUmx3dFRabmFWQUtzSW5oM3hsUFpyRjk5QTBNZlp1cV8zbkZGRXdsVVJWR3I5LUNxMWQ0RXNYUWVPMFBuOGFKSzJINTdMVUpMaUJmYVNhdmF1REUtdENSUHhQN2FOYzcxNC0zWlVkUGJtdnVteW5NYmFXN3QwVnN3MkpuWkE5TjE?oc=5","date":"2017-07-20","type":"regulatory","source":"drugdeliverybusiness.com","summary":"Braeburn, Camurus seek FDA nod for buprenorphine depot - drugdeliverybusiness.com","headline":"Braeburn, Camurus seek FDA nod for buprenorphine depot","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirgJBVV95cUxNQ2lVR2xGZjhmaVRmRlRSbWlGVm9PRUV1MmFNTHczZjNOQkFjT2ZpcTVWNEFDcDNMZHh4SkhuMDFxSEp4NXNxRnRJN2NHRGF0ZUNob3p5M0dkbHNGV09RajBnVzM4VXlJNDlBYi1naldrbUtrbUpKRVBySHNvTW5fRTlOVmVhT1ZBZmhaaXpjWHNLZjIzekFJZlNmeFBDbWJuZDFmZ1B2SEpJTC1vSTBFcjFEWWlTN2hTS05tQjN5cmxfVTBKcVVUdnVfZlhHc2V2SEJhc0hTQzFueDBZNjlWNVZXSlo1ZHBlTlIyMzBqNmtrU2tKRE5fN2RnaDRqdE9Kb3FVdFlKa0ExRW82b3dIMUQ1MVVnajI0V1NTSllxUzVacHZrdElSb0dVSURlZw?oc=5","date":"2014-11-20","type":"deal","source":"prnewswire.com","summary":"Camurus and Braeburn Pharmaceuticals sign exclusive license for long-acting buprenorphine injectables for the treatment of opioid dependence and pain - prnewswire.com","headline":"Camurus and Braeburn Pharmaceuticals sign exclusive license for long-acting buprenorphine injectables for the treatment ","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":2},"enrichmentLevel":0,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}